GRI
GRI BIO Presents Phase 2a Biomarker Data on GRI-0621 in IPF at ERS 2026
New translational data from the 35-patient Phase 2a study point to a repair phenotype, with placebo-adjusted FVC of +99 mL at Week 12 and no serious drug-related events.
GRI
Market-moving news on GRI Bio (NASDAQ: GRI): filings, earnings, deals and other events, from REDFILED.